Cellectar Biosciences, Inc. (CLRB) vs Karyopharm Therapeutics Inc. (KPTI)
A side-by-side comparison of Cellectar Biosciences, Inc. and Karyopharm Therapeutics Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
CLRB
Cellectar Biosciences, Inc.
$1.51HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
KPTI
Karyopharm Therapeutics Inc.
$0.65HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
Total return — CLRB vs KPTI
growth of $100 · dividends reinvested · last 10yCLRB -100.0% (-55.5%/yr)KPTI -99.5% (-41.6%/yr)KPTI compounded faster over this window
Log scale — wide-divergence pair
CLRB KPTI
CLRB vs KPTI: by the numbers
- •KPTI is the larger company ($15M vs $12M market cap).
- •Both run net losses; CLRB's is the smaller (0.00% vs -153.28% net margin).
Metrics side by side
Valuation
| Metric | CLRB | KPTI |
|---|---|---|
| P/S ratio | N/A | 0.10 |
| P/B ratio | 0.40 | N/A |
Profitability
| Metric | CLRB | KPTI |
|---|---|---|
| Gross margin | 0.00% | 95.88% |
| Operating margin | 0.00% | -56.17% |
| Net margin | 0.00% | -153.28% |
| ROE | -74.73% | N/A |
| ROIC | -74.94% | N/A |
Growth (annualized)
| Metric | CLRB | KPTI |
|---|---|---|
| Revenue CAGR (5Y) | N/A | 7.47% |
| Total return CAGR (5Y) | -60.51% | -62.18% |
Frequently asked
- How have CLRB and KPTI total returns compared?
- Over the past 10 years, CLRB delivered -55.35% and KPTI delivered -41.85% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.